Tags: Drug.

Neratinib (HKI-272) is a tyrosine kinase inhibitor under investigation for the treatment breast cancer and other solid tumours.It is in development for the treatment of early- and late-stage HER2-positive breast cancer.Like lapatinib and afatinib it is a dual inhibitor of the human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases.

Neratinib_skeletal.svg
ATC prefix
none
CAS number
698387-09-6
FDA UNII code
JJH94R3PWB
IUPAC name
(2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
PubChem
9915743

Loading...

This page contains content from the copyrighted Wikipedia article "Neratinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.